Search
Now showing items 1-1 of 1
Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse
(2020)
Background: Ovarian cancer is fifth leading cause of the cancer related death in women. Platin based doublet regimen plus bevacizumab is standard treatment in relapse. The primary aim of this study is to define clinicopathological ...